Article Figures & Data
Figures
- Figure 1
Kaplan-Meier survival curves showing time to failure (TTF) survival according to CEA (A) D-dimer (B).
- Figure 2
Kaplan-Meier survival curves showing overall survival (OS) according to D-dimer (A), CEA (B), and CA19-9 (C).
Tables
No. of patients Percentage Age (mean 67 years) < 67 17 48.6 ≥ 67 18 51.4 Gender Female 18 51.4 Male 17 48.6 Symptom Yes 30 85.7 No 5 14.3 Weight loss Yes 15 42.9 No 20 57.1 Neoadjuvant chemotherapy Yes 11 31.4 No 24 68.6 Type of surgery DP 14 40 DP + adrenalectomy 12 34.3 DP + other 9 25.7 T T1 1 2.9 T2 18 51.4 T3 16 45.7 N N0 18 51.4 N1 15 42.9 N2 2 5.7 Perineural invasion Yes 26 74.3 No 9 25.7 AJCC stage I 9 25.7 II 24 68.6 III 2 5.7 IORT dose (Gy) 12 1 2.9 15 27 77.1 20 7 20.0 Applicator diameter (cm) 2 4 11.5 3 16 45.7 4 13 37.1 5 2 5.7 Pre-operative CA19-9 (U/mL) < 37 15 42.9 ≥ 37 20 57.1 Pre-operative CEA (ng/mL) < 5 24 68.6 ≥ 5 11 31.4 D-dimer (ng/mL) < 500 10 28.6 ≥ 500 25 71.4 Adjuvant chemotherapy Yes 31 88.6 No 4 11.4 Adjuvant chemotherapy Gemcitabine 3 8.6 S1 5 14.3 Gemcitabine + S1 8 22.9 Gemcitabine + albumin-bound paclitaxel 9 25.7 Albumin-bound paclitaxel + S1 2 5.7 FOLFIRINOX 4 11.4 DP, distal pancreatectomy; AJCC, American Joint Committee on Cancer; IORT, intraoperative radiation therapy; CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; S1, tegafur, gimeracil and oteracil potassium capsules; FOLFIRINOX, fluorouracil + leucovorin + irinotecan + oxaliplatin.
- Table 2
Univariate analysis of associations of patient, tumor, treatment, and pathologic characteristics with survival
Variable Time to failure survival Overall survival 95% CI P value 95% CI P value TNM stage 4.906–18.427 0.216 7.128–41.206 0.007* IORT dose ≤ 15 (vs. > 15) 2.382–12.818 0.530 0.001–56.159 0.984 D-dimer < 500 (vs. ≥ 500) 4.906–18.427 0.005* 10.267–38.067 0.016* CEA < 5 (vs. ≥ 5) 4.906–18.427 0.036* 7.790–20.610 0.002* CA19-9 < 37 (vs. ≥ 37) 0.715–16.219 0.112 10.520–18.946 0.001* ↵*P < 0.05 was considered statistically significant. CI, confidence interval.
- Table 3
Multivariate analysis of associations of patient, tumor, treatment, and pathologic characteristics with survival
Variable Time to failure survival Overall survival HR 95% CI P value HR 95% CI P value TNM stage 1.393 0.59–3.289 0.449 0.125 0.006–2.384 0.350 IORT dose ≤ 15 (vs. > 15) 0.389 0.139–2.157 0.547 2.120 0.473–9.509 0.326 D-dimer < 500 (vs. ≥ 500) 0.219 0.070–0.682 0.009* 0.230 0.070–0.763 0.016* CEA < 5 (vs. ≥ 5) 0.384 0.159–0.928 0.034* 0.281 0.109–0.725 0.009* CA19-9 < 37 (vs. ≥ 37) 0.666 0.282–1.569 0.352 0.234 0.079–0.692 0.009* ↵*P < 0.05 was considered statistically significant. HR, hazard ratio; CI, confidence interval.
Variable No. (%) Pancreatic fistula 33 (94.2) A 30 (85.7) B 2 (5.7) C 1 (2.9) Delayed gastric emptying 7 (20.0) A 3 (8.6) B 4 (11.4) Intra-abdominal abscess 1 (2.9) Multiple organ failure 1 (2.9)
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.